21 related articles for article (PubMed ID: 23993328)
1. Simm530, a novel and highly selective c-Met inhibitor, blocks c-Met-stimulated signaling and neoplastic activities.
Wang Y; Zhan Z; Jiang X; Peng X; Shen Y; Chen F; Ji Y; Liu W; Shi Y; Duan W; Ding J; Ai J; Geng M
Oncotarget; 2016 Jun; 7(25):38091-38104. PubMed ID: 27191264
[TBL] [Abstract][Full Text] [Related]
2. Identification of Atuveciclib (BAY 1143572), the First Highly Selective, Clinical PTEFb/CDK9 Inhibitor for the Treatment of Cancer.
Lücking U; Scholz A; Lienau P; Siemeister G; Kosemund D; Bohlmann R; Briem H; Terebesi I; Meyer K; Prelle K; Denner K; Bömer U; Schäfer M; Eis K; Valencia R; Ince S; von Nussbaum F; Mumberg D; Ziegelbauer K; Klebl B; Choidas A; Nussbaumer P; Baumann M; Schultz-Fademrecht C; Rühter G; Eickhoff J; Brands M
ChemMedChem; 2017 Nov; 12(21):1776-1793. PubMed ID: 28961375
[TBL] [Abstract][Full Text] [Related]
3. Recent advances in c-Met-based dual inhibitors in the treatment of cancers.
Jin F; Lin Y; Yuan W; Wu S; Yang M; Ding S; Liu J; Chen Y
Eur J Med Chem; 2024 Jun; 272():116477. PubMed ID: 38733884
[TBL] [Abstract][Full Text] [Related]
4. Studying the Binding Modes of Novel 2-Aminopyridine Derivatives as Effective and Selective c-Met Kinase Type 1 Inhibitors Using Molecular Modeling Approaches.
Ye Q; Fu C; Li J
Molecules; 2020 Dec; 26(1):. PubMed ID: 33374386
[TBL] [Abstract][Full Text] [Related]
5. Data driven polypharmacological drug design for lung cancer: analyses for targeting ALK, MET, and EGFR.
Narayanan D; Gani OABSM; Gruber FXE; Engh RA
J Cheminform; 2017 Jul; 9(1):43. PubMed ID: 29086093
[TBL] [Abstract][Full Text] [Related]
6. Discovery of 3H-imidazo[4,5-b]pyridines as potent c-Met kinase inhibitors: design, synthesis, and biological evaluation.
Chen D; Wang Y; Ma Y; Xiong B; Ai J; Chen Y; Geng M; Shen J
ChemMedChem; 2012 Jun; 7(6):1057-70. PubMed ID: 22581753
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and c-Met kinase inhibition of 3,5-disubstituted and 3,5,7-trisubstituted quinolines: identification of 3-(4-acetylpiperazin-1-yl)-5-(3-nitrobenzylamino)-7- (trifluoromethyl)quinoline as a novel anticancer agent.
Wang Y; Ai J; Wang Y; Chen Y; Wang L; Liu G; Geng M; Zhang A
J Med Chem; 2011 Apr; 54(7):2127-42. PubMed ID: 21405128
[TBL] [Abstract][Full Text] [Related]
8. Design and optimization of a series of 1-sulfonylpyrazolo[4,3-b]pyridines as selective c-Met inhibitors.
Ma Y; Sun G; Chen D; Peng X; Chen YL; Su Y; Ji Y; Liang J; Wang X; Chen L; Ding J; Xiong B; Ai J; Geng M; Shen J
J Med Chem; 2015 Mar; 58(5):2513-29. PubMed ID: 25668160
[TBL] [Abstract][Full Text] [Related]
9. Discovery and optimization of novel 4-phenoxy-6,7-disubstituted quinolines possessing semicarbazones as c-Met kinase inhibitors.
Qi B; Mi B; Zhai X; Xu Z; Zhang X; Tian Z; Gong P
Bioorg Med Chem; 2013 Sep; 21(17):5246-60. PubMed ID: 23838381
[TBL] [Abstract][Full Text] [Related]
10. MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor.
Pan BS; Chan GK; Chenard M; Chi A; Davis LJ; Deshmukh SV; Gibbs JB; Gil S; Hang G; Hatch H; Jewell JP; Kariv I; Katz JD; Kunii K; Lu W; Lutterbach BA; Paweletz CP; Qu X; Reilly JF; Szewczak AA; Zeng Q; Kohl NE; Dinsmore CJ
Cancer Res; 2010 Feb; 70(4):1524-33. PubMed ID: 20145145
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and biological evaluation of 2-amino-5-aryl-3-benzylthiopyridine scaffold based potent c-Met inhibitors.
Zhang D; Zhang X; Ai J; Zhai Y; Liang Z; Wang Y; Chen Y; Li C; Zhao F; Jiang H; Geng M; Luo C; Liu H
Bioorg Med Chem; 2013 Nov; 21(21):6804-20. PubMed ID: 23993328
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic targeting of the receptor tyrosine kinase Met.
Sattler M; Ma PC; Salgia R
Cancer Treat Res; 2004; 119():121-38. PubMed ID: 15164876
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
